* If you want to update the article please login/register
Malaria is one of the tropical diseases that cause a high incidence of morbidity and mortality. It begins with parasite invasion and the destruction of infected red blood cells, triggering the release of parasite products that promote host immune response. During the last decade, research on the role of extracellular vesicles in several illnesses, including malaria, has grown dramatically. This article discusses the role of EVs in malaria immunopathogenesis.
Complement Receptor Type 1 is a malaria-associated gene that codes for a transmembrane receptor of erythrocytes and is essential for malaria parasite migration. Here, we investigate the history of malaria evolution by examining selection signals in the CR1 gene. Populations from East India's hyperendemic regions of Papua New Guinea and Papua New Guinea showed a large positive selection in populations from the hyperendemic zones of East India and Papua New Guinea. In addition, we found a variant rs3886100 under positive selection in West Africans that is also related to a poor level of CR1 expression in the brain. Our research shows the fine-resolution past of positive selection in the CR1 gene and highlights a population-specific history of malaria adaptation in CR1 genes. Notably, our novel strategy of using population genomic analysis results in the identification of protective variants that reduce the risk of malaria infection without the need for patient samples or individual medical records.
Background Although N. . . . ia has made some strides in malaria control, there are variations across states. We investigated the reasons behind the use of long-lasting insecticide-treated net and parasitaemia among under-five children in 13 states with high malaria prevalence. Grandchildren were more likely to use LLIN than others, but some families were less likely than others than children of household heads. LLIN use was more common in children whose parents' mother discovered that only weak children could die from malaria. Children whose mothers obtained net from antenatal or immunization clinics and campaigns were also more likely to use LLIN. Children aged 24-59 months compared to 0-11 months were more likely to have parasitaemia than those aged 0-11 months, according to those in whom fever was confirmed and children of uninitiated women were more likely to have parasitaemia. The risk of parasitaemia among children from poor families was higher than those from wealthy households compared to those from wealthy households. The odds of parasitaemia in rural children were 98% higher.
Source link: https://doi.org/10.1371/journal.pone.0268185
Background Malaria control activities can have a disproportionately greater effect on Plasmodium falciparum than on P. vivax in areas where both species are coendemic. Antimalarial treatment policy was updated to artemisinin combination therapy for uncomplicated malaria and intravenous artesunate for severe malaria in March 2006, according to any Plasmodium species. In the late transition period, the number of patients with malaria requiring admission to hospital decreased from 26. 9% in the pre-policy change period to 14. 0%, a difference of -12. 9%. Patients with P. falciparum malaria in the hospital were dramatically reduced, but not in patients with P. vivax malaria. The hospital's proportion of malaria due to P. vivax increased from 44. 9% to 53. 3% in the community clinics and from 32. 4% to 44. 1% over the same period. Since controlling for population growth and changes in treatment-seeking behaviour, the incidence of P. falciparum malaria decreased from 511 to 239 per 1,000 ppy, despite increasing incidences of P. vivax malaria in the United States decreased from 511 to 239 per 1,000 people, according to 239 per 1,000 py. P. falciparum malaria was reduced to a greater extent than P. vivax malaria. Both the blood and liver stages of malaria are common in coendemic areas, and the timely removal of malaria will require a safe and effective radical cure of both the blood and liver stages of the parasite.
Source link: https://doi.org/10.1371/journal.pmed.1002815
Background Artemether-lumefantrine is the most commonly used therapy for uncomplicated Plasmodium falciparum malaria. During the second and third trimester, remarkably lower cure rates and lumefantrine levels have been reported in young children and pregnant women. In order to determine optimal dosing regimens in all patient populations, the aim of this research was to investigate the pharmacokinetic and pharmacokinetic characteristics of lumefantrine and the pharmacokinetic characteristics of its metabolite, desbutyl-lumefantrine. Children under the age of 15 kg and 15-25 kg were 22. 2 percent and 13. 4% lower in children under the age of 15 years old, respectively, and 20. 2% lower in pregnant women than non-pregnant adults. Lumefantrine use decreased with increasing pre-treatment parasitaemia, and a dose limit on lumefantrine absorption was severe. According to a lesser extent, increasing the frequency of dosing in young children and pregnant women outside of the first trimester of the first trimester will be more effective than using higher individual doses in the new standard treatment regimen. After administration of intact tablets with fat, the model was built using venous plasma data from patients receiving intact tablets with fat, and evaluations of alternative dosing techniques were only representative of venous plasma after administration of intact tablets with fat. Conclusions Based on our results, revised AL dosing regimens for young children and pregnant women may increase drug exposure, but will need longer or more complicated schedules.
Source link: https://doi.org/10.1371/journal.pmed.1002579
Background Artemisinin-based combination therapies are the mainstay of the current treatment of uncomplicated Plasmodium falciparum malaria, but ACT resistance is spreading throughout Southeast Asia. According to previous reports, young children with malaria are under-dosed. Individual plasma piperaquine concentration-time data from 11 clinical studies in adults and children with uncomplicated malaria and healthy volunteers were collected and standardised by the WorldWide Antimalarial Resistance Network, who collected and standardised individual plasma piperaquine concentration-time data. After the introduction of the manufacturers' new recommended dose regimens, body weight influenced clearance and volume parameters significantly, resulting in lower piperaquine exposures in small children and adults compared to larger children and adults. With the recommended dosage regimen, small children and adults had 29. 4 ng/ml in comparison to 38. 1 ng/ml in larger children and adults. Each piperaquine dose case had a mean increase of 26. 7 percent in piperaquine bioavailability. An evidence-based optimised dose regimen was developed that would expose piperaquine exposure in all ages comparable to that seen in a typical adult with standard therapy but not in excess of the manufacturer's recommended dosage range. Conclusions The derived population pharmacokinetic model was used to develop a new dose regimen of dihydroartemisinin-piperaquine that is expected to have safe piperaquine exposures in all patients, even in small children with malaria. This was part of the studies that informed the World Health Organization technical guidelines authorship in the introduction of the newly published treatment guidelines.
Source link: https://doi.org/10.1371/journal.pmed.1002212
Background Following the therapy of falciparum malaria, there is a risk of Plasmodium vivax parasitaemia. This research sought to quantify this risk and the associated determinants using a population-based random cure strategy, which includes artemisinin-based combination therapy with a hypnozoitocidal antimalarial drug, would be helpful in determining populations in which a universal radical cure, which includes artemisinin-based combination therapy with a hypnozoitocidal antimalarial drug, would be beneficial. Methods and results A systematic review of Medline, Embase, Web of Science, and the Cochrane Database of Systematic Reviews found effectiveness studies of uncomplicated falciparum malaria treated with ACT in P. vivax-periodical areas between 1 January 1960 and 5 January 2018 identified by a systematic review. Multivariable Cox regression studies investigated the possibility of P. vivax parasitaemia at days 42 and 63, as well as other risk factors. Overall, 14,146 patients developed P. falciparum monoinfection and 1,195 mixed infection with P. falciparum and P. vivax, with P. falciparum and P. vivax. Following acute virax parasitaemia treatment of P. falciparum, which was 31. 1% after AM and 4. 5 percent after DP, and 41 percent after DP, the cumulative risk of vivax parasitaemia following initiation of vivax parasitaemia following vivax paraphrasedoutput was 41. 1% after AM, 8. 4% after AM, and 45 percent after DP. Patients with P. vivax parasitaemia in 42 days of follow-up were in patients living in areas of short relapse periodicity; patients treated with AL, AA, or AM; and patients with asymptomatic diarrhea who did not appear within 2 days. Conclusions P. falciparum malaria therapy was associated with a high risk of P. vivax parasitaemia in this meta-analysis, which varied widely between studies.
Source link: https://doi.org/10.1371/journal.pmed.1003393
Plasmodium falciparum, a malaria parasite in the human host, is exposed to multiple selection pressures. Here, we used RNA sequencing to determine gene expression in 44 parasite isolates that caused severe and uncomplicated malaria in Papuan patients. Our RNAseq also established novel links between disease severity and PfEMP1 transcripts, domains, and smaller sequence segments, as well as a confirmed all previously reported links between expressed PfEMP1 sequences and severe disease. These findings will help identify vaccine targets for severe malaria and show how parasites adapt to-or are chosen by-the host environment in severe malaria.
Source link: https://doi.org/10.1371/journal.pbio.2004328
Background Malaria is one of the top global and national public health threats, affecting millions of people each year and causing significant morbidity and mortality. Objectives The study was designed to determine malaria prevention and related factors among households of pastoral communities in Borena zone, Oromia's southern Ethiopia, 2022. Methodology A community-based cross-sectional research design was used from March first to 30, 2022, among 421 randomly selected simple random sampling households in pastoral communities of the Borena zone, from March first to 3022. Conclusion The overall malaria prevention rate among pastoral community households was 31. 6% [95%; CI = 287. 2]u201336. 4]. The absence of plasmodium parasites among children [AOR = 4. 3, 95% CI = 2. 8, 2. 8] is the most significant contributing factor in malaria prevention practice. [AOR = 1. 6, 95% CI = 1. 1, 1. 2, 95% CI = 1. 1] and the absence of plasmodium parasites among children [AOR = 3. 6, 95. 7 CI = 2. 8] and the absence of plasmodium parasites among children [AOR = 3. 2, FI = 2. 8, CI = 2. 6, 4. 6, CI = CI = 2. 8] To avoid incorrect use of the ITN, health extension workers should have to raise concern in the communities.
Source link: https://doi.org/10.1177/23333928221144555
However, previous studies have shown that a correlation exists between severity and transmission of malaria and variations in the gut microbiome, though only limited data exists regarding the temporal dynamics of the gut microbiome during a malarial infection. We'll look at how malaria affects the gut microbiome here, using a rhesus macaque model of relapsing malaria. We performed 16S sequencing on DNA isolated from rectal swabs of rhesus macaques over the course of an experimental malarial infection with Plasmodium cynomolgi and determined gut bacterial taxa abundance in primary and relapsing infections in this research. According to a comparison with healthy controls, acute malaria's rectal microbiome is enriched with commensal bacteria normally present in healthy animals' mucosa. At peak infection with P. cynomolgi, significant changes in the tryptophan-kynurenine immunomodulatory pathway were detected, according to a finding that had not previously been reported in the context of P. vivax infections in humans.
Source link: https://doi.org/10.3389/fcimb.2022.1058926
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions